Search results
CRISPR 'will provide cures for genetic diseases that were incurable before,' says renowned...
Live Science via Yahoo News· 2 months agoVirginijus Šikšnys (an older man with short brown hair and round glasses wearing a suit jacket)...
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
InvestorPlace via Yahoo Finance· 1 year agoThe 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work...
CRISPR Therapeutics and Dollar General have been highlighted as Zacks Bull and Bear of the Day
Zacks via Yahoo Finance· 5 months agoFor Immediate Release Chicago, IL – December 11, 2023 – Zacks Equity Research shares CRISPR...
After a decade, CRISPR gene editing is a 'revolution in progress.' What does the future hold?
USA TODAY via Yahoo News· 1 year agoMedical innovations typically take 17 years from the time a lightbulb goes off in a scientist's head...
How Jennifer Doudna's Life Has Changed Since Discovering CRISPR 10 Years Ago
Time via Yahoo News· 2 years agoDr. Jennifer Doudna in Berkeley, Calif., on Jan. 18, 2019. Credit - Anastasiia Sapon—The New York...
FDA Approves First CRISPR Treatment in U.S.
Time via Yahoo News· 5 months agoSickled blood cells forming clumps in a vessel Credit - Getty Images It was only 11 years ago that scientists Jennifer Doudna and Emmanuelle Charpentier...
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
TipRanks via Yahoo Finance· 1 week agoCRISPR Therapeutics (NASDAQ:CRSP) stock has been slowly heading lower in recent months, and I don’t...
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
Investor's Business Daily· 7 months agoCrispr Therapeutics is facing its make-or-break moment as experts point to a pivotal decision in...
What's Next For Gene-Editing Darling Crispr After Its 'Historic' First-Ever Approval?
Investor's Business Daily· 5 months agoCrispr Therapeutics just executed on a moonshot goal as it recently won U.K. approval for the first...
More Likely to 5X First: CRISPR Therapeutics vs. InMode
Motley Fool· 1 year agoOwning growth stocks in a bear market can be painful; fearful investors often flee to safety, and...
